Advertisement
U.S. markets closed
  • S&P 500

    4,604.37
    +18.78 (+0.41%)
     
  • Dow 30

    36,247.87
    +130.49 (+0.36%)
     
  • Nasdaq

    14,403.97
    +63.98 (+0.45%)
     
  • Russell 2000

    1,880.82
    +12.57 (+0.67%)
     
  • Crude Oil

    71.26
    +1.92 (+2.77%)
     
  • Gold

    2,020.80
    -25.60 (-1.25%)
     
  • Silver

    23.29
    -0.77 (-3.20%)
     
  • EUR/USD

    1.0764
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.2450
    +0.1160 (+2.81%)
     
  • GBP/USD

    1.2551
    -0.0043 (-0.34%)
     
  • USD/JPY

    144.8930
    +0.7020 (+0.49%)
     
  • Bitcoin USD

    43,812.30
    -282.36 (-0.64%)
     
  • CMC Crypto 200

    914.81
    +18.10 (+2.02%)
     
  • FTSE 100

    7,554.47
    +40.75 (+0.54%)
     
  • Nikkei 225

    32,307.86
    -550.45 (-1.68%)
     

UPDATE 1-South African drugmaker Aspen posts 4% drop in annual profit

(Adds context in paragraph 3 and revenue and dividend in paragraph 4)

JOHANNESBURG, Aug 30 (Reuters) - South African drugmaker Aspen Pharmacare on Wednesday posted a 4% drop in annual profit impacted by higher inflation and a drop in COVID-19 vaccine sales.

For the year ended June 30, Aspen recorded headline earnings per share of 14.05 rand, down from 14.61 rand a year earlier.

Aspen had bet big on a massive demand for COVID-19 vaccines emanating from Africa but as the panic around the pandemic waned it was left with a huge idle capacity, forcing it to scout for new partnerships for shoring up revenues and profits.

It posted annual revenue of 40.7 billion rand ($2.19 billion) and announced dividends of 3.42 rand, both up 5% over the previous year. ($1 = 18.5656 rand) (Reporting by Promit Mukherjee; editing by Jason Neely and Nick Zieminski)

Advertisement